Blood-brain barrier dysfunction in immuno-mediated neurological diseases
The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, incl...
Gespeichert in:
Veröffentlicht in: | Immunological medicine 2018-07, Vol.41 (3), p.120-128 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 128 |
---|---|
container_issue | 3 |
container_start_page | 120 |
container_title | Immunological medicine |
container_volume | 41 |
creator | Shimizu, Fumitaka Nishihara, Hideaki Kanda, Takashi |
description | The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown. |
doi_str_mv | 10.1080/25785826.2018.1531190 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_25785826_2018_1531190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2202198151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMottT-BGWPXrZOkmY3ualFrVDwoueQZBOJZDc12UX6793SKp48zTDz3jzmQ-gSwwIDhxvCas44qRYEMF9gRjEWcIKm-3m5X5z-6SdonvMHABBYcsHEOZpQEJSTmk7R-j7E2JQ6Kd8VWqXkbSqaXXZDZ3ofu2Ic-7Yduli2tvGqt03R2SHFEN-9UaFofLYq23yBzpwK2c6PdYbeHh9eV-ty8_L0vLrblGaJOZQUAFeWmorXGjQTmNZUKKq00qIm2ljOaqodrpYG20aBoa5iTmEuBGFgKZ2h68PdbYqfg829bH02NgTV2ThkSQgQLDhmeJSyg9SkmHOyTm6Tb1XaSQxyz1H-cJR7jvLIcfRdHSMGPT796_qhNgpuDwLfuZha9RVTaGSvdiEml1RnfJb0_4xvh8OBRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2202198151</pqid></control><display><type>article</type><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</creator><creatorcontrib>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</creatorcontrib><description>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</description><identifier>ISSN: 2578-5826</identifier><identifier>EISSN: 2578-5826</identifier><identifier>DOI: 10.1080/25785826.2018.1531190</identifier><identifier>PMID: 30938273</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Blood-brain barrier ; endothelial cell autoantibodies ; galectin-3 antibodies ; GRP78 autoantibodies ; immuno-mediated neurological diseases</subject><ispartof>Immunological medicine, 2018-07, Vol.41 (3), p.120-128</ispartof><rights>2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</citedby><cites>FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/25785826.2018.1531190$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/25785826.2018.1531190$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,27481,27903,27904,59120,59121</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30938273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Nishihara, Hideaki</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><title>Immunological medicine</title><addtitle>Immunol Med</addtitle><description>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</description><subject>Blood-brain barrier</subject><subject>endothelial cell autoantibodies</subject><subject>galectin-3 antibodies</subject><subject>GRP78 autoantibodies</subject><subject>immuno-mediated neurological diseases</subject><issn>2578-5826</issn><issn>2578-5826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kEFLAzEQhYMottT-BGWPXrZOkmY3ualFrVDwoueQZBOJZDc12UX6793SKp48zTDz3jzmQ-gSwwIDhxvCas44qRYEMF9gRjEWcIKm-3m5X5z-6SdonvMHABBYcsHEOZpQEJSTmk7R-j7E2JQ6Kd8VWqXkbSqaXXZDZ3ofu2Ic-7Yduli2tvGqt03R2SHFEN-9UaFofLYq23yBzpwK2c6PdYbeHh9eV-ty8_L0vLrblGaJOZQUAFeWmorXGjQTmNZUKKq00qIm2ljOaqodrpYG20aBoa5iTmEuBGFgKZ2h68PdbYqfg829bH02NgTV2ThkSQgQLDhmeJSyg9SkmHOyTm6Tb1XaSQxyz1H-cJR7jvLIcfRdHSMGPT796_qhNgpuDwLfuZha9RVTaGSvdiEml1RnfJb0_4xvh8OBRg</recordid><startdate>20180703</startdate><enddate>20180703</enddate><creator>Shimizu, Fumitaka</creator><creator>Nishihara, Hideaki</creator><creator>Kanda, Takashi</creator><general>Taylor & Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180703</creationdate><title>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</title><author>Shimizu, Fumitaka ; Nishihara, Hideaki ; Kanda, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4180-30016e3c687b0b5913739a3abab972bce8573bf164c1eda0c3f65fa1899250e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood-brain barrier</topic><topic>endothelial cell autoantibodies</topic><topic>galectin-3 antibodies</topic><topic>GRP78 autoantibodies</topic><topic>immuno-mediated neurological diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Nishihara, Hideaki</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimizu, Fumitaka</au><au>Nishihara, Hideaki</au><au>Kanda, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood-brain barrier dysfunction in immuno-mediated neurological diseases</atitle><jtitle>Immunological medicine</jtitle><addtitle>Immunol Med</addtitle><date>2018-07-03</date><risdate>2018</risdate><volume>41</volume><issue>3</issue><spage>120</spage><epage>128</epage><pages>120-128</pages><issn>2578-5826</issn><eissn>2578-5826</eissn><abstract>The blood-brain barrier (BBB) is the brain-specific endothelial cell barrier that is important for maintaining brain homeostasis and preventing the entry of toxic substances. Pathological BBB dysfunction is a critical step of the disease process in several immuno-mediated neurological diseases, including multiple sclerosis (MS), neuromyelitis optica (NMO), neuropsychiatric systemic lupus erythematosus (NPSLE) and neuro-Behçet diseases. The pathological findings from patients with secondary progressive (SP) MS, NMO and NPSLE showed leaky BBB in the active lesions. NMO is a disease with strong evidence of disease-specific and pathogenic autoantibodies (aquaporin 4 [AQP4] autoantibodies). In the development of NMO, circulating AQP4 autoantibodies need to pass through the BBB in order to reach AQP4 on the astrocyte endfeet. Strong evidence suggests that NPSLE is associated with the disruption of the BBB and NPSLE patients frequently have antibodies bound to endothelial cells in their sera. We recently identified two BBB-reactive autoantibodies in immuno-mediated neurological diseases: galectin-3 autoantibodies in SPMS and GRP78 autoantibodies in NMO. In the present review article, we describe the basic structure and cellular biology of the BBB, discuss recent insights regarding the pathophysiology of the BBB breakdown in the setting of immuno-mediated neurological diseases, and describe our recent findings of autoantibody-mediated BBB breakdown.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>30938273</pmid><doi>10.1080/25785826.2018.1531190</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2578-5826 |
ispartof | Immunological medicine, 2018-07, Vol.41 (3), p.120-128 |
issn | 2578-5826 2578-5826 |
language | eng |
recordid | cdi_crossref_primary_10_1080_25785826_2018_1531190 |
source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Blood-brain barrier endothelial cell autoantibodies galectin-3 antibodies GRP78 autoantibodies immuno-mediated neurological diseases |
title | Blood-brain barrier dysfunction in immuno-mediated neurological diseases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A44%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood-brain%20barrier%20dysfunction%20in%20immuno-mediated%20neurological%20diseases&rft.jtitle=Immunological%20medicine&rft.au=Shimizu,%20Fumitaka&rft.date=2018-07-03&rft.volume=41&rft.issue=3&rft.spage=120&rft.epage=128&rft.pages=120-128&rft.issn=2578-5826&rft.eissn=2578-5826&rft_id=info:doi/10.1080/25785826.2018.1531190&rft_dat=%3Cproquest_cross%3E2202198151%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2202198151&rft_id=info:pmid/30938273&rfr_iscdi=true |